Hearing OncoMed Pharmaceuticals Just Posted Abstract For ESMO For Saturday; Abstract Shows Navicixizumab & Weekly Paclitaxel In Ovarian Cancer Showed 44% Response Rate, vs 25% In Prior Trial
Benzinga_Newsdesk